Evidence map›Paper›PMID 36103645›Full record

ArticleJCO precision oncology2022

Identification of Novel PGR-NR4A3 Fusion in Extraskeletal Myxoid Chondrosarcoma and Resultant Patient Benefit From Tamoxifen Therapy.

H Catherine Wilbur, Dan R Robinson, Yi-Mi Wu, Chandan Kumar-Sinha, Arul M Chinnaiyan, Rashmi Chugh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

H Catherine WilburDepartment of Medicine, Division of Hematology and Oncology, and Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI.
Dan R RobinsonMichigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0002-2337-7439
Yi-Mi WuMichigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI.
Chandan Kumar-SinhaMichigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0002-8696-3400
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan School of Medicine, Ann Arbor, MI.
Rashmi ChughDepartment of Medicine, Division of Hematology and Oncology, and Rogel Cancer Center, University of Michigan School of Medicine, Ann Arbor, MI.ORCID 0000-0002-4633-6971

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Exploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4M
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3M
NCI NIH HHS P30 CA046592NCI NIH HHS R35 CA231996NCI NIH HHS U01 CA214170
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ChondrosarcomaNeoplasms, Connective and Soft TissueReceptors, SteroidDNA-Binding ProteinsGene FusionHumansReceptors, Thyroid HormoneTamoxifenDNA-Binding ProteinsNR4A3 protein, humanReceptors, SteroidReceptors, Thyroid HormoneTamoxifen

Identifiers

PMID36103645
PMCPMC9489176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.